Expansion of Lung V Alpha 14 NKT Cells by Administration of Alpha-Galactosylceramide-Pulsed Dendritic Cells

Jpn J Cancer Res. 2002 Apr;93(4):397-403. doi: 10.1111/j.1349-7006.2002.tb01270.x.


NKT cells, a novel murine lymphoid lineage bearing an invariant T cell receptor encoded by V alpha 14 and J alpha 281 gene segments, recognize a specific ligand glycolipid, alpha-galactosylceramide (alpha-GalCer) in a CD1d-dependent manner. Recent research has revealed that activated V alpha 14 NKT cells have dramatic antitumor effects against a wide variety of tumor cell lines in vivo and in vitro. Here, we demonstrate strong in vivo antitumor effects brought about by treatment with alpha-GalCer-pulsed dendritic cells in comparison with in vitro-activated V alpha 14 NKT cells. Furthermore, we show a significant expansion of endogenous V alpha 14 NKT cells in the lung following the administration of alpha-GalCer-pulsed dendritic cells. The feasibility of immunotherapy with alpha-GalCer-pulsed dendritic cells is discussed.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, CD1 / biosynthesis
  • Antigens, CD1d
  • Antineoplastic Agents / pharmacology
  • Cell Culture Techniques
  • Cell Line, Tumor
  • Cell Lineage
  • Cells, Cultured
  • Chromium Radioisotopes
  • Dendritic Cells / cytology*
  • Galactosylceramides / metabolism*
  • Galactosylceramides / pharmacology
  • Immunotherapy / methods*
  • Leukocytes, Mononuclear
  • Ligands
  • Lung / metabolism
  • Lung / pathology
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Neoplasm Metastasis
  • RNA / metabolism
  • Reverse Transcriptase Polymerase Chain Reaction


  • Antigens, CD1
  • Antigens, CD1d
  • Antineoplastic Agents
  • Chromium Radioisotopes
  • Galactosylceramides
  • Ligands
  • alpha-galactosylceramide
  • RNA